RUNX2 and acute myeloid leukemia: As a prerequisite, expression of the antigens CD33 or CD123 on the AML cell lines MOLM-13 and OCI-AML3 was confirmed and quantitatively determined using an anti-CD33 mAb and anti-CD123 mAb, respectively (Figure 2a,b).